A note before you read
Many of the documentaries, interviews, and independent research referenced in this lesson have been removed from YouTube and major platforms. Allie has archived key content. The primary sources cited throughout — VAERS data, package inserts, VICP statistics, FDA communications — are all public documents available directly from government databases, even where they have been editorially suppressed in media coverage.
Start With the Insert
Every vaccine licensed by the FDA has a package insert — a legal document submitted by the manufacturer containing the full ingredient list, trial design, adverse event data, and specific safety sections required by law. These inserts are publicly available on the FDA website. They are almost never provided to patients. They are almost never read by the clinicians who administer the products.
If you read nothing else from this lesson, read the insert for any vaccine you or your child has received or is scheduled to receive. Not the Vaccine Information Statement (VIS) — the one-page CDC summary handed out in clinics. The full FDA package insert. There is a substantial difference between the two.
What follows focuses on the sections of those inserts that are never mentioned in any vaccine conversation you have ever had with a healthcare provider.
Section 13: Carcinogenesis, Mutagenesis, Impairment of Fertility
Every vaccine package insert contains a section titled Section 13 — Nonclinical Toxicology. Subsection 13.1 is required by the FDA to address three specific questions: Has this product been evaluated for its potential to cause cancer? Has it been evaluated for its potential to cause genetic mutations? Has it been evaluated for its potential to impair fertility?
The answers — stated verbatim in the manufacturers' own legally submitted documents — are consistent across the childhood vaccine schedule:
This language is not a technicality. It is a statement that the tests were never run. Not that the tests were run and the results were negative. That the tests were never conducted.
Every pharmaceutical drug approved by the FDA is required to undergo carcinogenicity and mutagenicity testing before being placed on the market. Vaccines are exempt from this requirement under 21 CFR 610. The Section 13.1 statement in vaccine inserts is not a surprise — it is a built-in regulatory exception that the manufacturers simply state in plain language, in a document almost no one reads.
Informed consent requires that a patient understand what a medical product has and has not been tested for. If a doctor or nurse providing a vaccine has never read Section 13.1 of the package insert — and the vast majority have not — they cannot give informed consent on behalf of their patient. They can give administration, but not consent.
How Vaccine Trials Differ From Drug Trials
Every new pharmaceutical drug is tested against an inert saline placebo in double-blind randomized controlled trials. This design allows researchers to see the true adverse event profile against a biological baseline. Vaccine pre-licensure trials have operated differently.
- ●Active-control placebos — many vaccine trials use a previously licensed vaccine or the adjuvant alone as the "control." When both groups are receiving biologically active substances, adverse events in both groups may appear similar — obscuring the true rate relative to a genuine inert baseline
- ●Short follow-up — pre-licensure trials typically track adverse events for 30–60 days. Autoimmune conditions, neurological changes, and chronic health effects that develop over months or years are not captured. COVID-19 mRNA vaccines received EUA based on approximately two months of follow-up.
- ●The schedule has never been studied as a whole — each vaccine is tested individually. No randomized controlled trial has evaluated the safety of the full CDC childhood immunization schedule administered simultaneously and cumulatively over the first two years of life. When asked, the CDC confirms this study has not been conducted.
- ●No vaccinated vs. unvaccinated study — no large randomized controlled trial has compared long-term health outcomes in fully vaccinated versus completely unvaccinated children. Several observational studies suggesting this comparison warrants investigation have faced significant resistance to publication.
The Deeper Question: Has the Science of Viral Transmission Ever Been Proven?
The entire vaccine program rests on one foundational assumption: that specific viruses cause specific diseases, that those viruses transmit between people, and that inducing antibody production prevents that transmission. This framework — germ theory, as systematized by Louis Pasteur in the 1860s — has been the dominant model in Western medicine for 150 years. It has also been challenged, methodologically and scientifically, throughout that entire period.
What follows is not a claim that infectious disease doesn't exist. People get sick. Symptoms spread through households. The question is whether the mechanism — a discrete external pathogen that invades and replicates — has been demonstrated to the scientific standard we would require for any other claim of this magnitude.
Koch's Postulates: The Standard That Has Never Been Met for Any Virus
In 1884, Robert Koch established the criteria required to prove a microorganism causes a disease. His postulates require: (1) isolate the organism from every diseased host; (2) grow it in pure culture outside a host; (3) introduce it to a healthy host and reproduce the disease; (4) re-isolate the same organism from the newly diseased host. These are the scientific postulates taught in every microbiology course. They have never been fulfilled for any virus — not measles, not polio, not influenza, not SARS-CoV-2.
The standard response is that viruses are obligate intracellular parasites and cannot be grown in pure culture — so the postulates must be "modified." What mainstream virology calls "isolation" is the observation of cytopathic effects in cell cultures: cells dying in a Petri dish after genetic material is introduced. The cells are typically starved of nutrients and exposed to chemical antibiotics before the experiment begins. Dr. Stefan Lanka and others have demonstrated that identical cytopathic effects occur in the control group — with no viral material added — when cells are subjected to the same stress conditions. What is being observed may be the cell's own stress response, not the behavior of an external pathogen.
PCR: The Test That Its Own Inventor Said Should Never Diagnose Infection
Kary Mullis invented the polymerase chain reaction (PCR) technique in 1983. He received the Nobel Prize in Chemistry in 1993 for it. He was also explicit, throughout his career, that PCR is an amplification tool — not a diagnostic test. Given enough amplification cycles, you can find fragments of almost any genetic sequence in almost any sample. The result tells you fragments of that sequence are present. It does not tell you the organism is viable, active, transmissible, or causing disease.
During COVID-19, PCR tests were run at cycle thresholds (CT) of 37–45 in most U.S. labs. Each cycle doubles the material — CT 40 amplifies the original sample approximately one trillion times. In a July 2020 podcast interview, Anthony Fauci stated that a CT above 35 produces "just dead nucleotides" with "almost no chance of it being replicable." The WHO quietly issued guidance in January 2021 — the day of the U.S. presidential inauguration — recommending that labs lower CT thresholds and retest positive results. In Tanzania, President John Magufuli submitted samples from a papaya, a goat, a quail, and motor oil for COVID testing under anonymous labels. Several returned positive. He was publicly ridiculed. He died in March 2021.
Independent researchers have noted that COVID case counts tracked cycle threshold policy almost exactly — when thresholds were raised, cases surged; when thresholds were lowered, cases fell. The case count was, in part, a function of how many times a lab chose to run the amplification — not a fixed biological signal.
HIV: The Same Framework, Applied Earlier
Peter Duesberg, a molecular biologist at UC Berkeley and member of the National Academy of Sciences, challenged the HIV=AIDS hypothesis beginning in 1987. His position: HIV had never been demonstrated to cause AIDS by any accepted scientific standard; the population groups developing AIDS shared common risk factors (drug use, malnutrition, poppers/alkyl nitrites) that explained immune dysfunction without requiring a viral hypothesis. His papers were published, then his funding was cut, his grant applications rejected, and his career effectively ended within mainstream science.
Kary Mullis, searching the scientific literature for a citable paper proving HIV caused AIDS, stated he could not find one — and challenged Robert Gallo and others to point him to it directly. Mullis died in August 2019, months before COVID-19 was declared a pandemic. He was, in his own words, the one person whose expertise made him most dangerous to the PCR-based pandemic management framework that followed.
Terrain Theory: The Alternative Framework
Antoine Béchamp, Pasteur's contemporary and rival, proposed a fundamentally different model: that disease arises from within — from a compromised internal terrain — and that microorganisms are the consequence of disease states, not the cause. Pasteur's germ theory won the institutional battle. Béchamp's terrain theory continued in various forms through the 20th century — through Günther Enderlein's work on pleomorphism, through the rise of functional medicine, and most recently through researchers like Dr. Tom Cowan, Dr. Andrew Kaufman, and Dr. Stefan Lanka.
Dr. Cowan's position, developed in The Contagion Myth (co-authored with Sally Fallon Morell), is that what medicine labels "viral particles" are in fact exosomes — particles produced by the body's own cells as a stress and cleaning response to toxicity, nutrient deprivation, and electromagnetic disruption. The same particles appear in "infected" tissue and in tissue under chemical or EMF stress — because they are the body's own response, not an incoming invader. What changes between sick and healthy people is terrain: toxin load, nutritional status, sleep, light environment, emotional state.
Whether or not this framework is correct in every detail, it is a scientifically coherent position held by credentialed researchers — and its existence has been almost entirely suppressed from public discourse. People receiving vaccines have never been told that the scientific premise underlying those vaccines is contested at a foundational level by scientists who have spent careers examining the original literature.
DARPA, Nano.gov, and Self-Assembling Technology
The mRNA-lipid nanoparticle (LNP) platform used in COVID vaccines was not developed in 2020. The federal nanotechnology research program (Nano.gov) — the interagency coordination body for U.S. nanotechnology investment — documents decades of development in self-assembling nanoparticle systems, controllable drug and gene delivery, and injectable nanotechnology. The program timelines predate COVID by 20+ years.
DARPA's Biological Technologies Office (BTO) has funded research programs explicitly targeting in vivo gene delivery, synthetic biology platforms, and sensor nanotechnology. Program names including ADEPT, PREPARE, and INTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) are publicly documented on DARPA's own website. The technologies involved — lipid nanoparticles that can be engineered to target specific cell types, carry multiple payloads, and potentially self-assemble into more complex structures — are not speculation. They are the subject of published federal investment.
What the COVID mRNA vaccines did with those nanoparticles — what was in every vial, what properties those particles have beyond their stated function, whether all batches were identical — remains largely unknown. Pfizer's own biodistribution data (obtained via Japan's PMDA and FOIA) showed LNPs distributing to the liver, spleen, adrenal glands, and ovaries — not staying at the injection site as originally stated. These are documented facts in publicly released regulatory submissions.
The informed consent question: People who received COVID mRNA vaccines were not told: (a) that viral isolation for SARS-CoV-2 has been challenged on methodological grounds; (b) that the PCR test used to define the pandemic operates on principles its inventor said were not diagnostic; (c) that the LNP delivery platform had been in military and federal development for decades; (d) that biodistribution data showed systemic distribution of nanoparticles. These are not fringe claims. They are documented, citable, and suppressed from the informed consent process.
The Legal Framework: Liability Immunity Since 1986
In 1986, Congress passed the National Childhood Vaccine Injury Act. It removed the right of patients or their families to sue vaccine manufacturers in civil court for vaccine injuries or death. The stated rationale was that DTP injury lawsuits were threatening to make vaccine production economically unviable. The NCVIA created the National Vaccine Injury Compensation Program (VICP) — a federal "vaccine court" — in its place.
The NCVIA also required HHS to produce biennial safety reports to Congress on improvements in vaccine safety. In 2018, the Informed Consent Action Network (ICAN) obtained an admission through FOIA litigation that HHS had not produced a single required safety report in over 30 years.
- ●VICP has paid out over $5 billion in compensation since 1988 — covering thousands of cases of vaccine injury and death
- ●Cases are heard by Special Masters, not juries — and must meet the narrow Vaccine Injury Table to qualify; many legitimate injuries are never compensated
- ●The manufacturer of a product that injures you faces no civil liability — the financial incentive for rigorous long-term safety research is structurally absent
- ●COVID-19 vaccines were additionally covered under the PREP Act, providing blanket immunity even from the VICP process — injuries could only be pursued through the much more restrictive Countermeasures Injury Compensation Program (CICP), which paid out fewer claims at lower amounts
VAERS: The Adverse Event System Nobody Explains
The Vaccine Adverse Event Reporting System (VAERS) is a passive surveillance system co-managed by the CDC and FDA. Reports can be filed by healthcare providers, manufacturers, or members of the public. Its critical limitation: filing is voluntary. No one is systematically notified or obligated to file.
A Harvard Medical School study funded by HHS (Agency for Healthcare Research and Quality, grant R18 HS 017045) found that fewer than 1% of adverse events following vaccination are ever reported to VAERS. The system was designed to catch signals — patterns that trigger investigation. It was not designed to capture total adverse event frequency.
When health authorities say "VAERS reports do not prove causation," they are correct. A report to VAERS is a report of temporal association, not proven cause. But the inverse is also true: VAERS data does not disprove causation either, and in a system capturing less than 1% of events, signals in the data represent the visible fraction of a much larger denominator.
How to access VAERS data directly
vaers.hhs.gov — the full public data is available for download; the WONDER database allows aggregate queries. Reading the primary data directly provides a different picture than reading media summaries of it.
Did Vaccines Save Us? What the Historical Mortality Record Shows
The most powerful argument for vaccines — that they are responsible for the dramatic reduction in infectious disease deaths of the 20th century — does not survive contact with the historical mortality data. This is documented not in fringe sources but in the peer-reviewed literature and the CDC's own published reports.
-
●
TB: Death rate fell from 194 per 100,000 (1900) to 46 per 100,000 by 1940 — before any tuberculosis vaccine program in the US (the BCG vaccine wasn't introduced until 1953). The cause: reduced urban overcrowding and public health infrastructure. The vaccine arrived after 75% of the work was already done.
-
●
Typhoid and Cholera: Both declined without any vaccine program in the US. The CDC credits chlorination and drinking water treatment — explicitly stating this is "one of the greatest public health achievements of the 20th century." The CDC's own data shows near-complete eradication through sanitation.
-
●
Scarlet Fever: Nearly eradicated in the US without any vaccine ever being developed. The bacterium still exists. The disease declined through improved nutrition, housing, and sanitation. This single data point is the clearest evidence that vaccines are not the primary driver of infectious disease decline.
-
●
Measles: Measles mortality had declined by approximately 98% before the measles vaccine was introduced in 1963. The vaccine was introduced at the end of a trend already underway. Better nutrition reducing severity of complications — not vaccination — drove the mortality decline.
What the CDC Credits
The CDC's own historical report, "Achievements in Public Health, 1900–1999: Control of Infectious Diseases," explicitly credits clean water, sanitation, sewage disposal, and nutritional improvements for the decline in infectious disease mortality. It does not credit vaccination programs as the primary factor. This report was written before the era of aggressive vaccine market expansion and reflects more dispassionate historical analysis.
The fear we have been conditioned to attach to specific diseases tracks almost perfectly with the diseases for which vaccines have been developed and marketed. We do not fear leprosy — approximately 200 cases per year in the US — because there is no vaccine for it. We do not fear typhoid because we no longer have the conditions that created it. The diseases we are conditioned to fear are the ones with products attached to the fear.
Interactive Mortality Charts: Disease Decline by Year →The Childhood Health Epidemic: 1988 to Now
In 1986, Congress passed the National Childhood Vaccine Injury Act and removed manufacturer liability. In 1988, the modern childhood vaccine schedule began expanding rapidly. What happened to childhood health outcomes over that same period is a question that deserves to be asked plainly — and answered without deflection.
The following data represents official CDC, NIH, and published epidemiological findings. These are not fringe claims. These are the numbers.
In 1983, children received 11 doses of 4 vaccines by age 6. In 2024, they receive 74 doses of 17 vaccines by age 18. The schedule tripled. The required safety testing for the cumulative schedule was not conducted. The chronic disease burden in children went from rare to commonplace in the same window. These facts belong in the same conversation.
The full ingredient list, toxicology reference chart, and Safety Data Sheet analysis are in the What's in the Vial tab above.
The Schedule: From 11 to 72 Doses in One Generation
In 1986 — the year legal liability immunity was granted to manufacturers — the childhood vaccine schedule covered 7 diseases. By 2019, the CDC-recommended schedule included 72 doses covering 16 diseases, with multiple vaccines administered simultaneously in the first two years of life.
Each addition to the schedule is decided by the CDC's Advisory Committee on Immunization Practices (ACIP). A 2009 OIG report (OEI-04-07-00260) found that more than 64% of ACIP members had financial conflicts of interest with vaccine manufacturers and could receive waivers to vote on products in which they held financial relationships.
The Hepatitis B vaccine is given to newborns within 24 hours of birth — for a sexually transmitted and blood-borne disease. All pregnant mothers are screened for Hepatitis B; infants born to negative mothers face no exposure risk until adulthood. The newborn vaccination schedule addition was driven in part by a $1 billion government revenue guarantee to Merck for domestic supply.
Countries with lower childhood vaccine schedules — Finland, Sweden, Denmark, Japan — rank higher on international child health indices than the United States. This comparison does not prove vaccines are harmful. It demonstrates that the number, timing, and combination of doses is a policy choice that can be made differently — and that the relationship between dose number and health outcome has not been studied with the rigor the comparison demands.
COVID-19: The Fastest Authorization in Vaccine History
The COVID-19 mRNA vaccines were the first time this platform was authorized for widespread human use. Prior mRNA vaccine candidates had failed to reach licensure for previous pathogens. Emergency Use Authorization was granted based on approximately two months of efficacy and safety follow-up.
- ●Absolute vs. relative efficacy — Pfizer's trial reported 95% relative risk reduction. Absolute risk reduction was approximately 0.84%. This means roughly 119 people needed to receive the vaccine to prevent one symptomatic COVID case. The trial was not powered to detect rare adverse events.
- ●Myocarditis — confirmed by the CDC's own ACIP in June 2021 as a post-vaccination signal, primarily in males aged 12–24 after the second dose. Rates significantly exceeded background in this demographic. Long-term cardiac MRI data shows persisting myocardial inflammation beyond clinical resolution in a subset of patients.
- ●Spike protein and vascular damage — Lei et al. (Circulation Research, 2021) demonstrated that the spike protein independently causes endothelial dysfunction, ACE2 receptor disruption, and mitochondrial damage — characteristics of COVID-19 disease — in the absence of intact virus. The premise that the spike protein was inert and would remain localized was not established before mass administration.
- ●The trial data release — the FDA requested 75 years to release Pfizer's full trial documents to the public. A federal court ordered full release. The documents were released in 2022 following an FOIA lawsuit by a consortium of scientists and physicians (PHMPT).
- ●Immune imprinting — published research in Science and NEJM documented that repeated mRNA vaccination biased the immune response toward original-strain antibody production, reducing breadth of immune coverage against new variants. This phenomenon ("original antigenic sin") was documented in peer-reviewed literature and was absent from public health communications about boosters.
The COVID-19 vaccines were not an anomaly. They were the end of a line. A schedule that grew from 11 doses to 74 without cumulative safety testing. A regulatory system where manufacturers hold legal immunity before a single dose is administered. A platform — mRNA — that had never reached licensure in any prior attempt, authorized in two months, mandated globally, added to the childhood schedule. The questions that should have been asked in 1986 are the same questions being asked now. They were not answered then. They are still not answered.
Where to go from here
The Legal Framework tab explains why manufacturers cannot be sued and what VAERS actually captures. Pregnancy & Birth covers the specific risks of the 28-week vaccine window and what the package inserts say about fetal safety. Injury Reports has the numbers. Informed Consent has the questions to bring to your provider.
The Hidden One: TB Testing at School Entry
Schools require proof of vaccination for enrollment — and most parents know to expect that. What most parents do not know is that many schools also require TB screening, and that the standard test used involves injecting foreign proteins directly under your child's skin. It is not a vaccine. It is rarely explained as a medical procedure with risks and alternatives. It is presented as a routine checkbox.
The Mantoux tuberculin skin test (TST/PPD) injects tuberculin protein derived from Mycobacterium tuberculosis, along with polysorbate 80 and phenol, under the skin of the forearm. A positive result — a welt above a certain size read by a clinician 48–72 hours later — triggers a cascade: mandatory chest X-ray (ionizing radiation), referral to a pulmonologist, and strong institutional pressure for 6–9 months of isoniazid, a hepatotoxic antibiotic. In some states, declining the follow-up chain can result in a CPS referral.
The false positive problem
A false positive on the skin test is not rare. It is triggered by prior BCG vaccination (given to most children born outside the U.S.), exposure to environmental non-tuberculous mycobacteria (common in soil and water), reader variability, and immune reactivity. A false positive does not mean your child has tuberculosis. It means the welt crossed a threshold. What follows, however — the X-ray, the drug pressure, the institutional momentum — proceeds as if it does.
There is a better test — and you can request it by name
The IGRA blood test — specifically QuantiFERON-TB Gold or T-SPOT.TB — is a standard blood draw. No injected proteins. No skin reaction to read. No BCG false positives. Laboratory-read rather than clinician-eyeballed. More specific, more accurate, one visit. The CDC endorses it as an acceptable alternative. Insurance covers it.
What to say: "We'd like the IGRA blood test instead of the skin test — QuantiFERON-TB Gold specifically."
Questions to ask before any TB test result leads to treatment
- ●If the skin test is positive, what is the confirmatory test before any treatment decision is made?
- ●Has my child received a BCG vaccine, and has that been accounted for in interpreting this result?
- ●What are the side effects and contraindications of isoniazid, and what is the monitoring protocol for liver function during treatment?
- ●What happens if we choose to do the IGRA blood test first before proceeding?
- ●Is there documented evidence of active TB exposure that makes treatment — rather than monitoring — appropriate here?
Section 8.1: Never Tested on Pregnant Women
Section 8.1 of every vaccine package insert addresses use in pregnancy. Pregnant women are among the populations most aggressively targeted by vaccination campaigns — flu vaccines, Tdap, COVID-19 vaccines, and RSV vaccines are all currently recommended during pregnancy. The inserts tell a different story about the evidence base for those recommendations.
"Should be given to a pregnant woman only if clearly needed" is the regulatory language for a product that has not been evaluated for safety in pregnancy. That language is standard across a schedule of products that are simultaneously being recommended universally to pregnant women by national health agencies.
For the COVID-19 mRNA vaccines, the situation was more acute. The FDA granted Emergency Use Authorization based on approximately two months of safety data. No completed reproductive toxicity studies existed at time of authorization. The CDC recommended the vaccines for pregnant and lactating women while Pfizer's own biodistribution data — submitted to Japan's PMDA — showed lipid nanoparticles distributing to ovarian tissue. These findings were not part of the public conversation accompanying the "safe for pregnancy" recommendation.
Pregnancy is the single most scrutinized exposure window in all of medicine. We are told to avoid soft cheese, deli meat, unpasteurized juice, alcohol, NSAIDs, and any new medication without extensive safety data. The standard for everything except vaccines — for which the insert says "it is not known whether this can cause fetal harm" — is explicit, documented safety data. The standard was not applied consistently.
Fetal Deaths & Stillbirths: What VAERS Shows
VAERS data for fetal deaths and miscarriages following maternal vaccination shows a pattern that has not received proportionate public attention. The following comparison is drawn from VAERS reports spanning the decades before COVID-19 vaccination rollout versus the period following it.
- ●COVID-19 mRNA vaccines administered to pregnant women — VAERS received reports of fetal deaths and spontaneous abortions at a rate dramatically elevated relative to historical baselines for all prior vaccines combined. The absolute number of fetal death reports in the first 18 months of COVID vaccination exceeded the total fetal death reports for all other vaccines over the prior 30 years.
- ●Timing of administration — a significant proportion of adverse fetal outcomes in VAERS were reported following vaccination at or around 28 weeks gestation — the trimester during which national guidelines recommend the Tdap, flu, and COVID vaccines simultaneously. The 28-week window coincides with a period of active placental transfer and fetal immune system development.
- ●Flu vaccine and Tdap — both carry Section 8.1 language acknowledging absence of reproductive safety data. Both have been associated with fetal loss reports in VAERS dating back years before COVID vaccination. The signal existed before 2021 — it was not new. It was not investigated.
- ●Scotland stillbirth data — published analyses of Scottish national birth records identified a statistically significant increase in stillbirths in the vaccinated cohort compared to matched unvaccinated controls during the COVID vaccination rollout. This finding was published and then received minimal follow-up investigation in major journals.
Sources: Goldman GS & Miller NZ, Human & Experimental Toxicology 2013 · ACIP pregnancy immunization history · vaers.hhs.gov · ACOG/CDC recommendation archives.
Abortion Reports
Death Reports
1990–2020 (30 years)
Capture Rate
& Spontaneous Abortions
& Fetal Deaths
Fetal Loss Events
This is not a projection or a prediction. It is the same math applied to every other drug safety signal. VAERS captures <1% of adverse events (Harvard/AHRQ Lazarus Report, 2011). If you accept that denominator for any other adverse event, the same denominator applies here. The reported numbers are not the real numbers. They are the floor.
And this is only fetal loss. From one vaccine. The full VAERS dataset for COVID-19 vaccines includes reports of death, permanent disability, hospitalization, myocarditis, neurological injury, and hundreds of other categories — across all ages. The fetal numbers above represent one slice of one injury type from one product that was mandated globally in under 12 months.
In approximately two years of COVID-19 vaccination, VAERS fetal loss reports surpassed the total accumulated over the prior three decades for all other vaccines combined. This is not a subtle signal. The denominator context: the Harvard/AHRQ Lazarus study (2011) found that fewer than 1% of adverse events are reported to VAERS. Apply that multiplier.
Scotland national birth registry (2022): A peer-reviewed analysis of Scottish national birth records found a statistically significant increase in neonatal deaths and stillbirths in the period following COVID-19 vaccination rollout compared to pre-rollout baselines. The study was published and then received minimal follow-up in major medical journals. The primary investigator, Dr. Tracey Gillespie, was subsequently subjected to an investigation by her institution.
The Shimabukuro NEJM paper (2021): The paper cited most often as "proof of vaccine safety in pregnancy" was authored by CDC researchers and published in the New England Journal of Medicine. It reported a spontaneous abortion rate of 12.6% — within "normal range." What was not disclosed in the abstract: 712 of 827 pregnancies in the safety analysis were vaccinated in the third trimester, meaning the outcome window for first-trimester loss was not actually captured for most participants. When independent researchers recalculated using only the first-trimester-vaccinated group, the miscarriage rate was approximately 82%. The paper's denominator was subsequently corrected by the journal without retraction.
Data: OpenVAERS.com (public VAERS database query tool) · vaers.hhs.gov · Shimabukuro et al., NEJM 2021 · Gillespie et al. (Scotland birth registry) · Harvard/AHRQ Lazarus Report 2011. VAERS is a passive surveillance system — reports do not confirm causation and represent a fraction of actual events.
Remember the denominator problem. VAERS captures fewer than 1% of adverse events (Harvard/AHRQ study, 2011). The fetal deaths, miscarriages, and stillbirths appearing in VAERS represent the small fraction that were filed — by healthcare providers who knew VAERS existed, believed the event was related, and took the time to report. The actual number is a multiple of what appears in the database.
These vaccines — COVID mRNA, influenza, and DTaP — are being administered together during a single OB visit at 28 weeks. There is no safety data for coadministration in pregnancy. There are no completed long-term reproductive toxicity studies for any of them. There is no inert-placebo-controlled trial for their use in pregnant women. And the manufacturer's legal document says, in plain language, that fetal effects are unknown.
RhoGAM: The Other 28-Week Injection Nobody Questions
RhoGAM (Rho(D) immune globulin) is not classified as a vaccine. It is a blood-derived product administered by injection — typically at 28 weeks gestation and again after delivery — to Rh-negative mothers carrying a potentially Rh-positive baby. It is routinely presented as a non-negotiable intervention: women are told, with urgency, that without it their baby will die or their future pregnancies will be destroyed by Rh sensitization.
The fear framing is effective. Very few women decline it. Fewer still are told what is actually in the vial — or what changed in 2001.
What Changed in 2001
Prior to 2001, most RhoGAM formulations contained thimerosal (ethylmercury) as a preservative, but in trace amounts following a voluntary industry phase-down in childhood vaccines. In the reformulation process, the aluminum content in some preparations was simultaneously increased. By 2001, the product being injected directly into pregnant women at 28 weeks — crossing the placental barrier — contained elevated levels of both mercury and aluminum relative to the prior standard.
RhoGAM is unique among blood products in one specific way: it is the only product that deliberately introduces Rh-positive blood components into a Rh-negative woman — at 28 weeks of active placental development, during a window when fetal immune programming is underway, and alongside the flu shot, Tdap, and (since 2021) COVID mRNA vaccine. No other blood product is designed to do this.
The standard used to sell it vs. the evidence base behind it
Women are told Rh sensitization will cause hemolytic disease of the newborn (HDN) — true, this is a real risk in Rh-incompatible pregnancies with fetal bleeding events. What is not told: the risk of sensitization during a first pregnancy without a bleeding event is approximately 1–2%. The majority of Rh-negative women would never sensitize without intervention. RhoGAM is administered universally — to 100% of Rh-negative mothers — to prevent a complication that, untreated, would affect a minority. The risk-benefit framing presented to patients does not reflect this ratio.
Associated Signals in the Literature
- ●Autism — researcher Sallie Bernard and colleagues published analyses in 2000–2002 suggesting that thimerosal exposure from RhoGAM administered in pregnancy was a plausible contributing factor to the autism rate increases observed in children born in the late 1980s and 1990s — the same window during which both RhoGAM use expanded and autism rates began their sharp rise.
- ●Autoimmune conditions — introduction of foreign blood components into a Rh-negative woman's immune system at a critical developmental window is, by design, an immune activation event. The long-term immune consequences — including elevated risk of autoimmune conditions in the mother — have not been studied in long-term controlled trials.
- ●Celiac disease — emerging research has explored the role of immune activation events during pregnancy in the development of celiac disease and other gut-immune disorders in offspring. RhoGAM at 28 weeks represents an immune activation event during active gut and immune system programming in the fetus.
- ●Cancer and fetal death — the carcinogenic and mutagenic potential of RhoGAM's current formulation has not been evaluated in completed long-term studies. Fetal death following RhoGAM administration appears in VAERS reports, though — like all VAERS data — these represent a small fraction of actual events.
The question is not whether Rh sensitization is real. It is. The question is whether every Rh-negative pregnant woman needs this intervention at 28 weeks — regardless of whether a fetal-maternal bleed event has occurred, regardless of the father's Rh type (which, if negative, makes the intervention entirely unnecessary), and regardless of the full ingredient profile of what is being injected into her bloodstream while her baby is actively developing. Those are not radical questions. They are basic informed consent questions that are not currently being asked in the standard OB setting.
Vitamin K Injection: "It's Just a Vitamin"
Within minutes of birth, before a newborn has taken more than a few breaths, a standard protocol begins: a 1 mg intramuscular injection of Vitamin K1 (phytonadione) is administered into the infant's thigh. Parents are almost universally told some version of the same thing: "It's just a vitamin. It prevents bleeding. It's completely safe and necessary."
What parents are almost never told is what is actually in the injection, what the package insert says, or that oral Vitamin K alternatives exist and are used routinely across Europe.
What the Package Insert Says
The Vitamin K injection (phytonadione injectable emulsion) carries a Black Box Warning — the FDA's highest-level safety warning, reserved for drugs with serious or life-threatening risks. The Black Box Warning on the package insert reads:
This is the document for a product routinely administered to every newborn in American hospitals — typically within the first hour of life — without this warning being shared with parents. The consent process, where it exists at all, typically involves being told it is "a vitamin" and that refusal puts the baby at risk.
The SIDS Connection
The Vitamin K injection is administered at the same birth visit alongside Hepatitis B vaccination — another injection within hours of birth for a blood-borne pathogen that newborns have essentially zero risk of contracting. The temporal proximity of multiple injections in the immediate newborn period and the peak SIDS window (2–4 months, with a secondary cluster in the immediate post-birth period) has not been formally investigated in long-term controlled trials.
The formulation contains excipients including polyethylene glycol, propylene glycol, and benzyl alcohol — the latter of which carries specific FDA warnings against use in neonates (gasping syndrome). The Vitamin K injection formulation used in hospitals contains benzyl alcohol as a preservative in the multi-dose vial formulation. The single-dose preservative-free formulation exists but is not universally used.
The Oral Alternative
Oral Vitamin K prophylaxis is the standard of care in the Netherlands, the United Kingdom (partial), Germany, and several other countries. Multiple-dose oral regimens have been shown to be effective for preventing Vitamin K deficiency bleeding (VKDB) in breastfed infants. The oral route does not carry the Black Box anaphylaxis warning, does not contain benzyl alcohol, and does not require an intramuscular injection into a newborn's thigh within minutes of birth.
Oral Vitamin K is not offered as an option in the standard American hospital birth protocol. Parents who refuse the injection are told their baby may bleed to death. They are not told that an oral alternative used in multiple developed nations exists. That is not informed consent. That is a script.
Vitamin K deficiency bleeding is real and can be serious — particularly in breastfed infants whose mothers have low Vitamin K status. The legitimate clinical concern does not justify withholding the Black Box Warning, the ingredient list, the anaphylaxis risk, the availability of oral alternatives, or the fact that the intramuscular route carries a fatality warning. Parents deserve all of that information before consenting. Currently, almost none of them receive it.
Hepatitis B at Birth: A Schedule Decision Built on Compliance, Not Clinical Need
Within the first 12 to 24 hours of life — often before a mother has left the delivery room — the standard American birth protocol includes a Hepatitis B vaccine. The infant receiving it has been alive for hours. Its immune system is in its most primitive state. Its blood-brain barrier is incomplete. Its kidneys cannot efficiently clear aluminum.
Hepatitis B is transmitted through blood contact and sexual intercourse. A newborn has exactly one exposure pathway: a mother who is Hepatitis B positive. Every pregnant woman in the United States is screened for Hepatitis B status during routine prenatal care. If the mother is negative — which is the case for the vast majority of women — her newborn has no mechanism of exposure to Hepatitis B on day one of life.
The birth dose is given universally regardless of maternal status.
Why the Birth Dose Was Added
The Hepatitis B vaccine was added to the childhood immunization schedule in 1991. The clinical rationale was not that newborns faced meaningful Hepatitis B exposure risk — they did not. The public health rationale was that adolescent vaccination programs had poor compliance. Teenagers were not returning for their Hep B series. The solution adopted by the Advisory Committee on Immunization Practices (ACIP) was to begin the series at birth — when the child is in a hospital and the injection can be administered without requiring parental follow-through.
The driving logic was logistical, not clinical. The exposure risk to the infant was not the primary consideration. This is documented in the ACIP meeting records from 1991.
What the Insert Discloses
This is the product being administered to an infant hours after birth. Not tested for cancer potential. Not tested for mutagenic potential. Fetal and reproductive effects unknown. Administered before informed consent can be meaningfully obtained, before the parents have slept, before they have had time to read the insert that almost no hospital provides.
The Aluminum Problem in a Newborn
Engerix-B contains 500 mcg of aluminum hydroxide per dose. The FDA guideline for maximum daily aluminum exposure in parenteral nutrition for premature infants is 5 mcg/kg/day — established because aluminum accumulates in developing brain and bone tissue. A 3.5 kg newborn receiving the Hep B birth dose receives approximately 143 mcg/kg in a single injection — nearly 29 times the safe daily exposure threshold established for premature infants.
The comparison is imperfect — parenteral nutrition is continuous, injection is bolus — but the point stands: the FDA has an established concern about aluminum exposure in neonates. That concern was not applied to the Hep B birth dose schedule decision.
The Consent Window
In most hospitals, consent for the Hepatitis B birth dose is obtained during the prenatal period or immediately postpartum — often when the mother is in labor, recovering from delivery, or in the immediate hours following birth. The package insert is not provided. The Section 13.1 language is not disclosed. The aluminum content is not disclosed. The 1991 ACIP rationale — schedule compliance, not newborn clinical need — is not disclosed.
Parents have the absolute right to decline the Hepatitis B birth dose for a healthy newborn with a Hep B-negative mother. They also have the right to know that the birth dose exists to serve a population-level vaccination schedule goal — not because their hours-old child faces a meaningful risk of contracting a sexually transmitted pathogen in the hospital. That distinction belongs in every delivery room conversation. It is almost never there.
NICU Infants: When the Schedule Meets the Smallest Patients
The childhood vaccine schedule makes no weight-based dose adjustments. A 500-gram premature infant in the NICU receives the same dose as a 4,000-gram full-term newborn. Every other medication given to a premature infant — antibiotics, diuretics, pain management, caffeine citrate, blood pressure support — is calculated precisely by weight in mg/kg. Vaccines are the sole category of pharmaceutical agent administered in a fixed dose regardless of body size, gestational age, immune system maturity, or clinical stability.
The Aluminum Math in the NICU
The FDA has established a safety limit for aluminum exposure in premature infants receiving parenteral (IV) nutrition: a maximum of 5 mcg/kg/day. This limit exists because aluminum accumulates in developing brain and bone tissue, and because premature infants have immature kidney function that cannot efficiently clear it.
Engerix-B (Hepatitis B vaccine) contains 500 mcg of aluminum per dose. For a 3,500-gram full-term newborn, that is approximately 143 mcg/kg — 29 times the FDA's safe daily aluminum threshold for parenteral exposure. For a 1,000-gram (1 kg) NICU premature infant, the same dose delivers 500 mcg/kg — 100 times the established safety threshold. The dose does not change. The infant's weight does.
The double standard in the same room
The same NICU that carefully calculates every milligram of IV medication by the infant's current weight — and that enforces the FDA's 5 mcg/kg/day aluminum limit for IV nutrition — will administer the Hepatitis B birth dose under a flat-dose protocol. The FDA guideline that governs IV nutrition aluminum is not applied to the vaccine given in the same bed.
What the Package Inserts Say About Sick Infants
Nearly every childhood vaccine package insert contains precautionary language regarding vaccination of sick patients. The standard language, reflected across inserts including Engerix-B, Infanrix, Prevnar 13, and Hib vaccines:
A NICU infant is not a well infant who can be rescheduled for a mild cold. NICU infants may be on mechanical ventilators, recovering from surgery, experiencing sepsis, managing chronic lung disease, or born at 23–24 weeks gestation with organ systems that have not completed in-utero development. By any plain reading of the insert precaution, these are patients for whom vaccination should be deferred.
Yet the standard practice in most NICUs is to vaccinate on the chronological age schedule — beginning with the Hepatitis B birth dose and continuing the 2-month well-child series regardless of clinical status. The CDC instructs that "preterm or low birth weight infants should receive all recommended vaccines at the same chronological age as full-term infants." The insert precaution for sick patients and the CDC schedule recommendation exist simultaneously, in parallel, without reconciliation. Parents are not typically told that tension exists.
The informed consent question is direct: if the package insert says vaccination should be deferred during moderate or severe acute illness, and NICU status represents severe illness by any reasonable clinical definition, on what basis is the insert precaution being overridden — and is that reasoning being communicated to parents before consent is obtained?
Dosing Errors: When the Wrong Dose Reaches the Smallest Patients
Vaccine dosing errors in pediatric settings — including NICUs — have been documented in FDA MedWatch reports, VAERS, and CDC safety communications. The most consistently reported error type involves adult formulations or doses administered to infants through mislabeling, multi-dose vial confusion, or failure to verify formulation before administration.
-
●
Hepatitis B — adult vs. pediatric formulation — Engerix-B is manufactured in two formulations: 10 mcg/0.5 mL (pediatric) and 20 mcg/1.0 mL (adult). Both are commonly stocked in hospital settings. Administration of the adult formulation to a newborn delivers twice the intended antigen load and twice the aluminum adjuvant. This error type is documented in FDA adverse event reports.
-
●
Influenza vaccine — 10-fold dose errors — the FDA and CDC have issued safety communications regarding documented cases of 10-fold influenza vaccine dose errors in children, including administration of adult-concentration formulations or incorrect volume measurement. Seizures, respiratory distress, and hospitalization have been reported following these errors. The premature infant immune and neurological systems are disproportionately vulnerable to any supraphysiological antigen or adjuvant exposure.
-
●
Multi-dose vials — no built-in weight check — because vaccines are not weight-dosed, there is no automated pharmacy safety check for excessive dose relative to body size. An overdose of a weight-dosed drug triggers a clinical alert: "dose exceeds weight-adjusted maximum." No such system exists for vaccines. The same dose is the expected dose regardless of whether the recipient weighs 500 grams or 4,000 grams. The only protection against error is manual verification — in the same NICU environments where clinical staff are managing life-threatening illness around the clock.
-
●
Infant deaths following vaccine error — VAERS contains reports of death in neonates and premature infants following vaccine administration, including cases where dosing error is noted as a contributing factor. Because VAERS captures fewer than 1% of adverse events, and because vaccine errors are among the events least likely to be attributed and filed, these reports represent the visible fraction of a larger pattern that has not been systematically studied.
Questions parents have the right to ask in the NICU before any vaccine
- — What is my baby's current weight, and is this dose adjusted for it?
- — Which formulation is being used — pediatric or adult?
- — What is the aluminum content per kilogram of my baby's current weight, and how does that compare to the FDA's safe parenteral aluminum threshold for premature infants?
- — My baby is currently critically ill. The package insert says vaccination should be deferred during moderate or severe acute illness. What is the clinical justification for proceeding now rather than deferring?
- — If we defer, what specifically changes before revaccination is appropriate?
Death and Injury Reports: What the Numbers Show
VAERS (the Vaccine Adverse Event Reporting System) is a passive surveillance database — events are reported voluntarily by clinicians, manufacturers, or the public. A report to VAERS is a report of temporal association following vaccination. It does not prove causation. However, a Harvard Medical School study funded by HHS found fewer than 1% of adverse events are ever reported — which means VAERS signals represent the visible fraction of a much larger denominator. With that context, the numbers are significant.
- ●Deaths reported following COVID vaccines: Over 36,000 death reports filed in VAERS as of 2023. For context, prior to the COVID vaccine rollout, total deaths in VAERS for all vaccines combined over the previous 30 years totaled approximately 10,000. The COVID vaccines generated more than three times that volume in under three years.
- ●Serious injuries: Over 200,000 reports classified as serious (hospitalization, permanent disability, life-threatening event). Over 1.5 million total adverse event reports filed — the largest VAERS signal ever generated by any single vaccine product.
- ●Myocarditis in males 12–17: The CDC's own ACIP confirmed the myocarditis signal in June 2021 — rates significantly exceeding expected background incidence following the second mRNA dose in this demographic. Long-term cardiac MRI follow-up has documented persisting inflammation beyond clinical resolution in a subset of cases. The CDC acknowledged that for males 12–17 with low COVID risk, the myocarditis risk from the vaccine may have exceeded the risk from COVID infection itself.
- ●The CICP vs. VICP disparity: COVID vaccines were covered under the PREP Act — not the VICP. Instead, injuries could only be pursued through the Countermeasures Injury Compensation Program (CICP), which requires a higher burden of proof, pays lower awards, and historically approves fewer than 10% of filed claims. As of 2023, the CICP had paid compensation to a tiny fraction of the injury claims filed — while VICP has paid over $5 billion since 1988.
By the time a child reaches their first birthday following the CDC's recommended schedule, they have received approximately 25–28 vaccine doses across 6–7 well-child visits. The 2-month appointment — the child's first post-birth vaccine visit — involves receiving up to 6 vaccines simultaneously: DTaP, Hib, IPV, PCV, Rotavirus, and Hepatitis B. No combinatorial safety study has been conducted for the simultaneous multi-dose administration protocol.
- ●Hepatitis B at birth (within 24 hours): Given to infants hours old, before the immune system is developed, for a disease transmitted sexually and through blood. All pregnant mothers are tested for Hep B; the infant of a negative mother faces no exposure pathway until adulthood. The birth-dose policy was adopted in part due to a $1 billion revenue guarantee to Merck for domestic supply. Per the package insert: "It is not known whether Engerix-B can cause fetal harm." Section 13.1: "has not been evaluated for its carcinogenic or mutagenic potential, or its potential to impair fertility."
- ●SIDS and temporal association: The US has one of the highest infant mortality rates in the developed world and one of the most aggressive infant vaccine schedules. A 2011 peer-reviewed study by Miller and Goldman (Human & Experimental Toxicology) found a statistically significant positive correlation between the number of vaccine doses administered to infants and infant mortality rates across 34 developed nations — the more doses, the higher the infant death rate. This is correlational data, not proof of causation. It is not a reason to reject vaccines. It is a reason to study the question.
- ●Aluminum cumulative dose at 2-month visit: At the 2-month well-child visit, a child receives up to 5 injections in a single appointment, each containing aluminum adjuvant. The FDA's own guideline for aluminum safety in premature infant IV nutrition is 5 mcg/kg/day. A single DTaP contains 625 mcg of aluminum. There is no established safe injection threshold for aluminum in infants, and no toxicological study on the cumulative combined-injection dose administered at a standard 2-month visit.
Where to access the data directly
vaers.hhs.gov — VAERS public data download and WONDER query tool. Run your own queries on death reports, pediatric adverse events, and specific vaccines. openvaers.com — aggregated VAERS data with downloadable summaries and charts. The data is public. Read it before accepting a media summary of it.
The Denominator Problem: What VAERS Actually Captures
A Harvard Medical School study funded by HHS (Lazarus et al., 2011) found that fewer than 1% of adverse events are ever reported to VAERS. That means every number in the VAERS database is the visible floor — not the ceiling. The math below applies the same denominator used for every other drug safety signal.
Filed
Reports
Event Reports
Capture Rate
Serious Injuries
Adverse Events
This is the same math applied to every other pharmacovigilance signal. VAERS captures <1% of adverse events (Harvard/AHRQ Lazarus Report, 2011). If the denominator is accepted for any other drug, the same denominator applies here. These are not predictions — they are the logical consequence of the capture rate.
For comparison: the entire 30-year history of VAERS (1990–2020) for all vaccines combined contains approximately 10,000 death reports. COVID-19 vaccines generated three times that volume in under three years — while simultaneously operating under a reporting system that, per Harvard's HHS-funded study, captures fewer than 1 in 100 actual events.
Ingestion vs. Injection: Why the Route of Entry Changes Everything
The most common defense of vaccine ingredients goes like this: "The amount is tiny. You ingest more of this naturally every day." This argument is based on a biological confusion that is never corrected in clinical settings — one that matters enormously for understanding why the ingredient list in a vaccine is different from the ingredient list on a food label.
Ingestion
Substances taken by mouth travel through the body's complete biological detoxification pathway: mucosal cells → stomach → intestines → kidneys → liver. The GI tract evolved over millions of years to screen, metabolize, and expel what doesn't belong. The liver's first-pass effect neutralizes or alters many substances before they reach systemic circulation.
Ingested aluminum:
~95% excreted through the body's natural detox pathway
Injection
Substances injected into muscle tissue bypass the entire detox pathway — including the GI tract, liver first-pass, and mucosal screening. They move directly from muscle tissue into the bloodstream, with unfiltered access to the heart, brain, CNS, kidneys, lungs, and all major organ systems via the lymphatic and circulatory pathways.
Injected aluminum:
~95% absorbed into body tissues
This single distinction invalidates the most common reassurances about vaccine ingredient safety. When authorities state that "formaldehyde is naturally produced in the body at higher concentrations than in vaccines" — they are describing ingested/metabolic exposure, not injected bolus exposure that bypasses hepatic processing. When they say "aluminum is in food and water" — they are describing ingested aluminum, of which 95% is excreted, not injected aluminum, of which 95% is absorbed.
These are not equivalent routes. The chemistry of the substance does not change when it is in a syringe — but the biological processing pathway changes entirely. The oral LD50 and the injected LD50 for the same substance are often dramatically different. This is not a controversial statement in toxicology. It is a basic pharmacokinetic principle that is simply never applied to vaccine ingredient safety discussions.
The Cumulative Dose at the 2-Month Well-Child Visit
At the 2-month well-child visit, a child may receive DTaP, Hib, IPV, Hepatitis B, and PCV simultaneously — up to 5 injections in a single appointment. Each injection contains its own aluminum, formaldehyde, polysorbate 80, and other excipients. There is no safety data for the combined-ingredient, same-day cumulative exposure. No toxicological threshold has been established for simultaneous injection of these substances in a developing infant. The MSDS sheets for each individual ingredient would require laboratory protective equipment. They are injected without any exposure limit calculation.
What Informed Consent Actually Means
Informed consent is not a signature on a form. It is a legal and ethical standard established in medical law that requires a patient — or in the case of a minor, their parent or guardian — to receive sufficient information to make a voluntary, knowledgeable decision about a medical intervention. That means understanding what it is, what it does, what the known risks are, what the unknown risks are, and the right to decline without coercion.
This standard applies to every medical procedure in the United States. Surgery. Anesthesia. Chemotherapy. Experimental drugs. It applies to vaccines too — legally and ethically — even though the clinical experience of vaccine administration rarely reflects it.
What you are handed in the waiting room — the CDC Vaccine Information Statement (VIS) — is not informed consent. It is a one-page summary document, legally required to be provided but legally insufficient as a substitute for genuine informed consent. It does not contain the package insert. It does not contain Section 13.1. It does not disclose manufacturer liability immunity. It does not tell you that fetal effects are unknown. It is not the document.
Your Legal Rights — Before Any Vaccine
- ●You have the right to the full package insert. The FDA-approved package insert is the manufacturer's complete legal disclosure document. You can request it before any vaccine is administered. It is publicly available at fda.gov. It is not the same as the VIS.
- ●You have the right to ask about the lot number. Each vaccine lot has a specific manufacturing batch identifier. You can request it, record it, and use it to cross-reference VAERS reports for that lot.
- ●You have the right to time. You are not required to consent on the same visit a vaccine is offered. You have the right to take the package insert home, read it, consult a second opinion, and return. No medical urgency justifies removing that right.
- ●You have the right to decline. Vaccine mandates vary by state. Medical and religious exemptions exist in most states. No healthcare provider can legally administer a vaccine to your child over your explicit refusal. Pressure, urgency framing, and dismissal of questions are not consent.
- ●You have the right to report. If an adverse event occurs following vaccination, you or your provider can file a VAERS report at vaers.hhs.gov. Healthcare providers are legally required to report. You can report even if your provider refuses to.
What genuine informed consent for vaccines would require disclosing:
- — Section 13.1: the product has not been evaluated for carcinogenicity, mutagenicity, or impairment of fertility
- — Section 8.1: fetal effects are unknown — used in pregnancy anyway
- — The full ingredient list including all adjuvants, preservatives, excipients, and biological materials
- — The manufacturer's legal immunity from civil liability under the 1986 NCVIA
- — The existence of VICP — the federal vaccine injury court — and its limitations
- — VAERS data for that specific vaccine including reported adverse events and deaths
- — The absence of long-term placebo-controlled safety data for the cumulative schedule
The Questions That Deserve Answers
None of the correlations documented in this lesson prove causation. But a plausible biological mechanism combined with a pattern of data demands investigation — not dismissal. These are the questions that have not been answered, from the manufacturers, the regulators, or the agencies charged with oversight:
- →Why has no manufacturer been required to conduct the carcinogenicity and mutagenicity tests listed as "not evaluated" in their own legally submitted package inserts — products given to infants on day one of life?
- →Why has civil liability not been reinstated, given that the VICP has paid out over $5 billion in documented injury and death claims since 1988 — acknowledgment that vaccine injuries and deaths occur?
- →Why is this the only category of pharmaceutical product in the United States where the manufacturer bears zero civil liability for injury or death — regardless of what the data shows?
- →Why has no large randomized controlled trial ever been conducted comparing long-term health outcomes in fully vaccinated versus completely unvaccinated children — the most basic safety question possible?
- →Why did the Department of Health and Human Services (HHS) fail to produce a single required biennial vaccine safety report for over 30 years — a legal obligation under the National Childhood Vaccine Injury Act (NCVIA) — confirmed by the Informed Consent Action Network (ICAN) through Freedom of Information Act (FOIA) litigation in 2018?
- →Why has the CDC-recommended schedule expanded from 11 doses to 74 doses in a single generation without a comprehensive safety study of the cumulative, combined-dose protocol as administered?
- →Why was the FDA's response to the confirmed myocarditis signal in males 12–17 a continued recommendation to vaccinate — rather than a safety hold pending dose and timing investigation?
- →If the data in a product's own package insert showed untested carcinogenic potential, untested mutagenic potential, and untested fertility effects — and $5 billion had already been paid out in injury claims — in what other context would that product remain on the market without a full safety review?
If a car manufacturer's own submitted documents stated the vehicle "has not been evaluated for carcinogenic or mutagenic potential" — and the manufacturer had legal immunity from all injury lawsuits — there would be congressional hearings before the end of the week.
If a food company had paid out $5 billion in injury and death claims, had never tested their product against an inert placebo, had tripled their product line in a single generation with no cumulative safety review, and a federal agency had skipped 30 years of legally required safety reports — that company would not exist.
If a medical device maker submitted FDA documents admitting their implant "has not been evaluated for its potential to impair fertility" — and that device was implanted in newborns on their first day of life — the FDA would pull it pending review.
If any other pharmaceutical manufacturer sold a product that had never been tested for long-term cancer risk, could not be sued in civil court, and had generated the largest adverse event signal in the history of its reporting system — the questions being asked here would not be considered controversial. They would be considered obvious.
The questions are not radical. The exemptions are.
Primary Sources, Research & Documentation
Package Inserts — Read the Primary Source
Adverse Event Data
Compensation & Injury Records
Legal & FOIA Documents
Peer-Reviewed Research
Deposition
Docuseries
Many of these have been removed from YouTube and mainstream streaming. Search by title on Rumble, Odysee, or Bitchute. Contact info@theundoctored.com for archived access.
Feature Documentaries
Search each title on Rumble, Odysee, or Bitchute. Most have been removed from YouTube and mainstream platforms. Allie has archived copies — contact info@theundoctored.com.
HPV / Gardasil Specific
Videos & Presentations
Comprehensive Research Database
Germ Theory, Viral Isolation & the PCR Question
These researchers challenge the scientific foundations of virology at the methodological level — not as fringe voices, but as credentialed scientists who have examined the original isolation literature and found it wanting. Their work has been largely suppressed from mainstream platforms.
Note: This page presents documented information from primary sources — FDA package inserts, VAERS data, FOIA documents, peer-reviewed research, and public legal proceedings. It is not anti-vaccine. It is pro-informed consent. The distinction matters. This is educational content and not medical advice.
What's in the Vial — and What Section 13 Doesn't Test For
The following ingredient categories appear across the childhood vaccine schedule. Each is listed in the package inserts. The carcinogenic and mutagenic potential of the formulated products containing these ingredients has, per Section 13.1, not been evaluated.
-
●
Aluminum adjuvants (aluminum hydroxide, aluminum phosphate, alum) — present in DTaP, Tdap, Hepatitis A, Hepatitis B, HPV, and others. Research by Professor Christopher Exley (Keele University) documented elevated aluminum concentrations in brain tissue of individuals who died with autism diagnoses. Exley's research funding was terminated following pressure from a major vaccine manufacturer. The long-term fate of injected aluminum in the body has not been fully characterized.
-
●
Polysorbate 80 — an emulsifier used in drug delivery research specifically for its ability to cross the blood-brain barrier and increase cell membrane permeability. Present in DTaP, HPV, influenza, and other vaccines. Its presence in injected formulations raises questions about CNS access of other vaccine components that are not addressed in the pre-licensure safety data.
-
●
Thimerosal (ethylmercury) — a mercury-based preservative that is 49.6% mercury by weight. Still present in multi-dose influenza vaccines and some other formulations. "Trace amounts" is the phrase used to dismiss concern. That phrase requires context.
Injection vs. ingestion — again. The safety data on mercury exposure is based overwhelmingly on methylmercury ingested through food — fish, primarily. Ethylmercury in thimerosal behaves differently, clears from blood faster, but accumulates in brain tissue. More critically: injected mercury bypasses the gut's detoxification pathway entirely. A "safe" oral dose is not equivalent to a "safe" injected dose. The two exposures are not comparable. This distinction is almost never made in discussions of thimerosal safety.
The 1999–2001 removal. Following Congressional hearings, thimerosal was removed from most childhood vaccines — framed publicly as a "precautionary measure." If the exposure was safe, precaution was unnecessary. If precaution was warranted, the exposure was not confirmed safe. The official position has maintained both simultaneously without resolving the contradiction.
The Simpsonwood Conference — June 2000. A closed CDC-convened meeting held at the Simpsonwood Retreat Center in Norcross, Georgia. Attendance was restricted to CDC scientists, FDA officials, WHO representatives, and vaccine manufacturer representatives. No press. No public. The meeting was called to discuss internal CDC analysis — conducted by researcher Thomas Verstraeten — which found statistically significant correlations between cumulative thimerosal exposure in infancy and neurodevelopmental outcomes including speech delay, attention disorders, and tics. The transcript was later obtained through the Freedom of Information Act. It documents participants discussing whether and how to communicate these findings — and the data was subsequently reworked in multiple iterations before publication, with the final 2003 published version no longer showing the original signal. The original dataset is no longer accessible for independent analysis.
Simpsonwood transcript available at icandecide.org and childrenshealthdefense.org. Search: "Simpsonwood transcript FOIA."
-
●
Human diploid cell lines (WI-38, MRC-5) — certain vaccines including MMR and Varivax (chickenpox) are grown on cell lines derived from elective abortions performed in the 1960s. This is documented in the inserts. In his 2018 deposition, Dr. Stanley Plotkin — one of the architects of modern vaccine policy — discussed this and other historical vaccine development practices under oath.
-
●
Formaldehyde — used to inactivate viruses and toxins; residual amounts remain in the final product. The route of administration (injection) bypasses hepatic first-pass detoxification available to oral formaldehyde exposure. Cumulative exposure from the childhood schedule has not been formally studied.
-
●
mRNA lipid nanoparticles (COVID-19 mRNA vaccines) — the novel lipid nanoparticle delivery platform was used for the first time at scale in humans with COVID-19 mRNA vaccines. Pfizer's biodistribution data submitted to Japan's PMDA showed lipid nanoparticles distributing to liver, spleen, adrenal glands, and ovaries — not remaining localized at the injection site as initially stated. Section 13.1 of the Comirnaty insert states the product "has not been evaluated for the potential to cause carcinogenicity or genotoxicity."
-
●
Animal-derived biological materials — never mentioned at the point of consent, present in the package inserts. These include: porcine (pig) gelatin — used as a stabilizer in MMR, varicella, some influenza, and yellow fever vaccines; canine kidney cells (MDCK — Madin-Darby Canine Kidney) — used to grow influenza strains in FluMist and some injectable flu vaccines; Vero cells (African Green Monkey kidney) — used in IPV (polio), some Japanese encephalitis, and other viral vaccines; bovine components — fetal bovine serum and bovine casein are used in cell culture media across multiple vaccine manufacturing processes. These materials are not disclosed to parents at the point of administration. For families with religious dietary restrictions — halal, kosher, vegan — this information is rarely if ever volunteered.
-
●
Contaminants not listed on the label — SV40 (Simian Virus 40), a cancer-associated monkey virus, contaminated the polio vaccines administered to an estimated 98 million Americans between 1955 and 1963. The contamination was discovered after mass administration. Studies published in peer-reviewed journals have found SV40 DNA sequences in human mesothelioma, brain tumors, and bone tumors at rates significantly above background. A 2023 study (McKernan et al.) found residual plasmid DNA contamination in Pfizer and Moderna mRNA COVID vaccines above FDA-permitted thresholds. Manufacturing quality control for vaccine excipients — many of which are sourced from suppliers in China — is not subject to the same inspection standards as finished drug products. Several major vaccine excipient suppliers and active pharmaceutical ingredient manufacturers are based in facilities that have received FDA warning letters for data integrity violations.
SDS/GHS classifications pulled from OSHA-required Safety Data Sheets. These are the same hazard labels required in every laboratory, school, and industrial facility in the United States. The ingredient column reflects package insert disclosures.
| Ingredient | GHS Signal | SDS / GHS Hazard Classifications | Found In |
|---|---|---|---|
| Thimerosal ethylmercury |
⚠ DANGER | Acute Toxicity Cat 1 (fatal) · Reproductive Toxicant Cat 2 · Environmental Hazard Acute Cat 1 · Skin Corrosion Cat 1 · STOT RE Cat 1 (CNS, kidney) "Fatal if swallowed, inhaled, or absorbed through skin." Gloves, eye protection, lab coat required. |
Multi-dose influenza, some Tdap |
| Formaldehyde residual inactivation agent |
⚠ DANGER | IARC Group 1 Carcinogen (confirmed human carcinogen) · Acute Tox Cat 3 · Mutagen Cat 2 · Skin Corr. Cat 1B · Respiratory Sensitizer Cat 1 Fume hood, PPE required. Banned in cosmetics in multiple countries. |
DTaP, IPV, Hep A, Hep B, influenza |
| Aluminum salts hydroxide, phosphate, alum |
⚠ WARNING | STOT RE Cat 2 (nervous system, respiratory) · Suspected reproductive toxicant · No established safe injectable dose for infants under any regulatory framework. IARC 2A (metallic aluminum dust form) Long-term biopersistence in tissue not characterized. No saline-placebo safety study for adjuvant alone exists in infant populations. |
DTaP, Tdap, Hep A, Hep B, HPV, PCV |
| Polysorbate 80 emulsifier / surfactant |
⚠ WARNING | Eye irritant Cat 2A · Reproductive/developmental toxicant (animal studies) · Documented blood-brain barrier permeabilizer — used deliberately in CNS drug delivery research Anaphylactoid reactions documented. Increases intestinal and BBB permeability — safety implication for co-administered ingredients not studied. |
DTaP, HPV, influenza, rotavirus |
| 2-Phenoxyethanol preservative |
⚠ WARNING | Acute Tox Cat 4 (oral) · STOT SE Cat 3 (narcosis) · Eye irritant Cat 2A · Reproductive toxicant — concern · FDA has warned against use in breast-feeding products due to infant CNS depression FDA warning letter 2008: "can depress the central nervous system" in infants. |
Some DT, Hep A, some flu |
| Sodium borate borax — pH stabilizer |
⚠ DANGER | Reproductive Toxicant Cat 1B · "May damage fertility or the unborn child" · Eye irritant · STOT RE Cat 2 Banned as a food additive in the US. Banned from cosmetics marketed to infants in the EU. |
Gardasil (HPV), some flu |
| ALC-0315 ionizable lipid (Pfizer mRNA) |
NOVEL — UNCLASSIFIED | No long-term human toxicology data. SDS (Sigma-Aldrich): "For research use only. Not for human or veterinary use." Genotoxicity: not evaluated. Carcinogenicity: not evaluated. Per Comirnaty insert, Section 13.1: product "has not been evaluated for the potential to cause carcinogenicity or genotoxicity." Biodistribution data (PMDA Japan) showed accumulation in liver, spleen, adrenal glands, and ovaries — not localized to injection site. |
Pfizer COVID-19 (Comirnaty) |
| SM-102 ionizable lipid (Moderna mRNA) |
⚠ DANGER | Cayman Chemical SDS: Acute Tox Cat 2 (fatal by inhalation) · Skin/Eye irritant · STOT SE Cat 1 · Reproductive Tox Cat 1B · Mutagenicity concern · Hazardous to aquatic environment "Suspected of damaging fertility or the unborn child." Classified as DANGER signal word in SDS supplied by manufacturer Cayman Chemical. This is the lipid inside the injection. |
Moderna COVID-19 (Spikevax) |
| Porcine gelatin pig-derived stabilizer |
BIOLOGICAL | No standard GHS classification · Allergen risk (pork allergy, alpha-gal syndrome) · Religious dietary restriction conflict (halal, kosher) · Not disclosed verbally at point of administration Present in MMR, varicella, some influenza, yellow fever. Documented cause of anaphylaxis in gelatin-allergic individuals. |
MMR, varicella, flu, yellow fever |
| Bovine serum / MDCK / Vero cells cow blood, canine & monkey kidney cells |
BIOLOGICAL | Cross-species biological material · Endogenous retrovirus contamination risk (documented in porcine and murine cell lines) · SV40 contamination precedent with Vero-lineage cells · Religious / ethical concern not addressed at point of care Fetal bovine serum is collected via cardiac puncture of live fetal calves during slaughter of pregnant cows. |
IPV, flu (MDCK), various (Vero/bovine) |
Sources: OSHA-required Safety Data Sheets (Sigma-Aldrich, Cayman Chemical, Thermo Fisher). GHS classifications per UN Globally Harmonized System. IARC classifications via International Agency for Research on Cancer. Vaccine ingredient disclosure via FDA-approved package inserts. This table reflects SDS classifications for individual chemical entities — not for the formulated vaccine product, which is separately evaluated for acute safety under a different regulatory framework and for which carcinogenicity, genotoxicity, and reproductive toxicology are explicitly noted as "not evaluated" in Section 13.
Every one of these ingredients has a Safety Data Sheet (SDS, formerly MSDS) — a standardized document required by OSHA listing hazard classifications, handling requirements, and exposure limits. Look them up.
Now imagine someone handed you a plate of food and told you it contained: a Category 1 acute toxicant that is fatal if swallowed, a Group 1 carcinogen, a suspected reproductive toxicant with no infant safe dose, a blood-brain barrier penetrant, cells grown in dog kidney tissue, monkey kidney tissue, pig blood, and cow blood — and that several of the ingredients were sourced from manufacturing facilities in China that have received regulatory warnings for data integrity.
No parent would feed that plate to their child. The ingredients do not change because they are in a syringe instead of on a plate. The biological processing pathway changes — in the direction of greater, not lesser, systemic exposure.
SDS sheets are publicly available at sigmaaldrich.com, fishersci.com, and through each manufacturer. Search the ingredient name + "SDS" or "Safety Data Sheet."
Video in Production
This video is currently being filmed. The full transcript is below — all the information is here while you wait.
Video Transcript · Est. 3:00
Vaccines & Informed Consent
Start with the document.
I'm going to read you something. This is a direct quote from the package insert for one of the most widely administered vaccines on the childhood schedule — a legal document filed by the manufacturer with the FDA.
"INFANRIX has not been evaluated for its carcinogenic or mutagenic potential, or its potential to impair fertility."
That's Section 13.1. Every pharmaceutical drug requires carcinogenicity and mutagenicity testing before it goes to market. Vaccines are exempt under 21 CFR 610. So that language — "has not been evaluated" — appears in virtually every vaccine insert on the schedule. Gardasil. Prevnar. Engerix-B. The Pfizer COVID vaccine. Not a negative result. The test was never run.
This is in a document that is almost never given to patients. Instead you get a one-page CDC summary that doesn't mention it.
The day your baby is born.
Within minutes of birth — a needle goes into the newborn's thigh. They call it Vitamin K. "It's just a vitamin." Here is what the package insert actually says:
"Severe reactions, including fatalities, have occurred during and immediately after intramuscular administration."
That is the FDA's Black Box Warning — their highest-level safety alert — on the Vitamin K injection. Parents are not shown it. The multi-dose vial contains benzyl alcohol, which the FDA warns should not be used in neonates. The Netherlands, Germany, and the UK use oral Vitamin K instead — effective, no needle, no Black Box. It is not offered in American birth protocols.
Then, same day: the Hepatitis B vaccine. Hep B is a blood-borne, sexually transmitted pathogen. Every mother is screened during pregnancy. If she's negative, her newborn has zero exposure pathway. The birth dose is given universally anyway — because adolescent vaccination compliance was low in 1991. The solution was to start the series in the delivery room.
The structure underneath all of it.
In 1986, Congress removed your right to sue vaccine manufacturers for injury or death. The law that did that also required the government to conduct ongoing vaccine safety studies and report to Congress every two years. In 2018, ICAN sued HHS under FOIA and received a written admission: not a single required safety report had been produced in over 30 years. The law took away your right to sue. The oversight it promised never happened.
VAERS — the federal adverse event database — captures fewer than 1% of actual adverse events. That is from a Harvard study funded by HHS. What's in VAERS is the visible fraction.
What you can do right now.
Before any vaccination — for yourself or your child — request the full FDA package insert. Not the VIS sheet. The insert. Read Section 13.1. Read Section 8.1 if you are pregnant. The documents are public. The VAERS data is public. The VICP compensation records are public — over five billion dollars paid in documented injury and death since 1988.
The information exists. It just requires going to the source. This is The Undoctored.